The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Androgen Receptor– and E2F-1–Targeted Thymoquinone Therapy for Hormone-Refractory Prostate Cancer
Abstract
Relapse of prostate cancer after androgen ablation therapy is hormone-refractory, with continued tumor growth being dependent on the androgen receptor (AR). E2F-1, a regulator of cell proliferation and viability, reportedly plays a role in the development of hormone-refractory prostate cancer. Thymoquinone is a component of Nigella sativa, an herb used for thousands of years for culinary and medicinal purposes in Asian and Middle Eastern countries and has been reported to have an antineoplastic effect both in vitro and in vivo. We observed that thymoquinone inhibited DNA synthesis, proliferation, and viability of cancerous (LNCaP, C4-B, DU145, and PC-3) but not noncancerous (BPH-1) prostate epithelial cells by down-regulating AR and E2F-1. In LNCaP cells, this was associated with a dramatic increase in p21Cip1, p27Kip1, and Bax. Thymoquinone blunted progression of synchronized LNCaP cells from G1 to S phase, with a concomitant decrease in AR and E2F-1 as well as the E2F-1-regulated proteins necessary for cell cycle progression. In a xenograft prostate tumor model, thymoquinone inhibited growth of C4-2B–derived tumors in nude mice. This in vivo suppression of tumor growth, as with C4-2B cell growth in culture, was associated with a dramatic decrease in AR, E2F-1, and cyclin A as determined by Western blot of tissue extracts. Tissue immunohistochemical staining confirmed a marked reduction in E2F-1 and showed induction of apoptosis on terminal deoxyribonucleotidyl transferase–mediated dUTP nick end labeling assay. These findings show that thymoquinone suppresses the expression of AR and E2F-1 necessary for proliferation and viability of androgen-sensitive as well as androgen-independent prostate cancer cells both in vitro and in vivo and, moreover, produced no noticeable side effects in mice. We conclude that thymoquinone, a naturally occurring herbal product, may prove to be effective in treating hormone-sensitive as well as hormone-refractory prostate cancer. Furthermore, because of its selective effect on cancer cells, we believe that thymoquinone can also be used safely to help prevent the development of prostate cancer. [Cancer Res 2007;67(16):7782–8]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients
Bubendorf, L., Schöpfer, A., Wagner, U., Sauter, G., Moch, H., Willi, N., Gasser, T. C., & Mihatsch, M. J. (2000) · Human Pathology · doi:10.1053/hp.2000.6698 · Cited by 1,895
Cited by
Gupta, S. C., Kim, J. H., Prasad, S., & Aggarwal, B. B. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9235-2 · Cited by 806
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Strebhardt, K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3184 · Cited by 653
Thymoquinone: Potential cure for inflammatory disorders and cancer
Woo, C. C., Kumar, A. P., Sethi, G., & Tan, K. H. B. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.09.029 · Cited by 541
Thymoquinone and its therapeutic potentials
Darakhshan, S., Bidmeshki Pour, A., Hosseinzadeh Colagar, A., & Sisakhtnezhad, S. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.011 · Cited by 507
Cancer Prevention With Natural Compounds
Gullett, N. P., Ruhul Amin, A. R. M., Bayraktar, S., Pezzuto, J. M., Shin, D. M., Khuri, F. R., Aggarwal, B. B., Surh, Y.-J., & Kucuk, O. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.06.014 · Cited by 485
Metadata
- Authors
- Kaseb, A. O., Chinnakannu, K., Chen, D., Sivanandam, A., Tejwani, S., Menon, M., Dou, Q. P., & Reddy, G. P.-V.
- Venue
- Cancer Research
- Published
- 2007-08-15
- Volume
- 67
- Issue
- 16
- Pages
- 7782-7788
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2161996879
- Cited by
- 231
- References
- 2
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Androgen Receptor– and E2F-1–Targeted Thymoquinone Therapy for Hormone-Refractory Prostate Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-07-1483
- The paper
- Kaseb, A. O., Chinnakannu, K., Chen, D., Sivanandam, A., Tejwani, S., Menon, M., Dou, Q. P., & Reddy, G. P.-V. (2007). Androgen Receptor– and E2F-1–Targeted Thymoquinone Therapy for Hormone-Refractory Prostate Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-07-1483
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.